GlassScriptPhysician profile
David P Herrick
NPI 1205982998
$9,416.55
in general payments reported to CMS, 2019-2025
33 companies · $1,236 in 2025
The $1,236 reported for 2025 was more than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $859 · 2020: $1,528 · 2021: $1,790 · 2022: $1,434 · 2023: $934 · 2024: $1,634 · 2025: $1,236.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,804.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,804.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $5,883.26 | 2019-2025 | Proclaim, Eterna |
| Boston Scientific Corporation | $1,346.13 | 2019-2025 | Infinion 16, Infinion 16, General - Therapies |
| Collegium Pharmaceutical, INC. | $493.96 | 2019-2025 | Xtampza, Belbuca |
| Forte Bio-Pharma LLC | $288.38 | 2022-2025 | Prolate, Nalocet, Tanlor |
| Mml US, INC. | $259.22 | 2024 | Reactiv8 |
| Biodelivery Sciences International, INC. | $136.53 | 2019-2021 | |
| Curonix LLC | $97.95 | 2024 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Si-Bone, INC. | $91.59 | 2024 | |
| Scilex Pharmaceuticals INC. | $77.43 | 2019-2024 | |
| Stimwave Technologies Incorporated | $71.54 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $69.66 | 2019-2021 | |
| Arbor Pharmaceuticals, INC. | $67.70 | 2019-2021 | |
| Amgen INC. | $51.15 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $45.19 | 2019-2021 | |
| Allergan, INC. | $43.94 | 2021 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Spr Therapeutics, INC | $40.33 | 2024 | Sprint Pns System |
| Lilly USA, LLC | $37.82 | 2019-2020 | |
| Vertos Medical, INC. | $34.28 | 2020 | |
| Ossur Americas, INC. | $29.55 | 2025 | |
| Pacira Pharmaceuticals Incorporated | $24.87 | 2025 | Zilretta |
| Abbvie INC. | $24.30 | 2022 | |
| Saluda Medical Americas, INC. | $23.76 | 2025 | Evoke |
| Vertex Pharmaceuticals Incorporated | $22.00 | 2024 | |
| Novartis Pharmaceuticals Corporation | $21.37 | 2019 | |
| Nevro Corp. | $20.96 | 2019 | |
| Idorsia Pharmaceuticals US INC | $16.65 | 2022 | |
| Merz Pharmaceuticals, LLC | $15.54 | 2023 | Xeomin |
| Assertio Therapeutics, INC. | $14.95 | 2019 | |
| Medtronic USA, INC. | $14.82 | 2019 | |
| Neuronetics, INC. | $14.30 | 2022 | |
| Pfizer INC. | $13.51 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $12.83 | 2019 | |
| Redhill Biopharma INC. | $11.08 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Herrick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.